Biodexa - BDRX Net earnings per share for the last four quarters

Public company logo of Biodexa Pharmaceuticals (BDRX)

The low environmental footprint of the office format has no impact on share prices; therefore, the 12-month YoY EPS growth rates reflect market dynamics, with the indicator holding around 98.50. Biodexa Pharmaceuticals (BDRX) is developing proprietary drug delivery methods to combat brain cancer. The company's capital is based on the commercialization of targeted therapy and the execution of clinical trials.

Biodexa (BDRX): Net earnings per share (EPS TTM) from 02/11/2024 to 11/17/2026

Financial and market metric breakdowns for Biodexa (BDRX)

Fundamental company valuation:BDRX - Biodexa Pharmaceuticals
Core merchandise of Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals (BDRX) maintains a monopoly in targeted drug delivery for brain cancer therapy, allowing the company to exercise significant pricing power. This indicator measures the percentage change in earnings per share over the last twelve months relative to the same period last year. It reflects the pace at which operational successes are capitalized and the efficiency of cost management. The stability of this value confirms the resilience of the business model. By analyzing the annual volatility of net income per share TTM, an investor determines the fairness of the asset's market valuation.